NB
Therapeutic Areas
Bright Minds Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Epilepsy Program | Drug-Resistant Epilepsy | Preclinical |
| PWS Program | Prader-Willi Syndrome (Hyperphagia/Compulsive Behaviors) | Preclinical |
| Neuropsychiatry Franchise | Unspecified Neuropsychiatric Disorders | Discovery |
| Pain Franchise | Unspecified Pain Conditions | Discovery |
Leadership Team at Bright Minds Biosciences
IM
Ian McDonald
Chief Executive Officer, Director
JT
Jan Torleif Pedersen
Director, Chief Science Officer
SD
Stephen D. Collins
Chief Medical Officer
RC
Ryan Cheung
Chief Financial Officer
JD
Jianmin Duan
Vice President of Pharmacology
AV
Alex Vasilkevich
Chief Operating Officer, Senior Scientific Officer
JF
Jeremy Fryzuk
Director
DW
David Weiner
Non-Executive Director